Next Article in Journal
Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging
Next Article in Special Issue
Management of Small Bowel Neuroendocrine Tumors
Previous Article in Journal
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)

Treatment Options for Pancreatic Neuroendocrine Tumors

Institute of Endocrinology, Beilinson Hospital, Petach Tikva 49100, Israel
Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
Department of Endocrine Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 1Z5, Canada
Department of Medicine, Division of Endocrinology and Metabolism, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada
Department of Pathology, University Health Network, University of Toronto, Toronto, ON M5S 1A1, Canada
Author to whom correspondence should be addressed.
Cancers 2019, 11(6), 828;
Received: 24 May 2019 / Revised: 6 June 2019 / Accepted: 12 June 2019 / Published: 14 June 2019
(This article belongs to the Special Issue Management of Neuroendocrine Neoplasms)
The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy. View Full-Text
Keywords: neuroendocrine tumors; pancreas; pancreatic cancer neuroendocrine tumors; pancreas; pancreatic cancer
Show Figures

Figure 1

MDPI and ACS Style

Akirov, A.; Larouche, V.; Alshehri, S.; Asa, S.L.; Ezzat, S. Treatment Options for Pancreatic Neuroendocrine Tumors. Cancers 2019, 11, 828.

AMA Style

Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S. Treatment Options for Pancreatic Neuroendocrine Tumors. Cancers. 2019; 11(6):828.

Chicago/Turabian Style

Akirov, Amit, Vincent Larouche, Sameerah Alshehri, Sylvia L. Asa, and Shereen Ezzat. 2019. "Treatment Options for Pancreatic Neuroendocrine Tumors" Cancers 11, no. 6: 828.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop